AUDIT, RESEARCH AND GUIDELINE UPDATE

Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)


ABSTRACT

The UK Refractory Asthma Stratification Programme (RASP-UK) will explore novel biomarker stratification strategies in severe asthma to improve clinical management and accelerate development of new therapies. Prior asthma mechanistic studies have not stratified on inflammatory phenotype and the understanding of pathophysiological mechanisms in asthma without Type 2 cytokine inflammation is limited. RASP-UK will objectively assess adherence to corticosteroids (CS) and examine a novel composite biomarker strategy to optimise CS dose; this will also address what proportion of patients with severe asthma have persistent symptoms without eosinophilic airways inflammation after progressive CS withdrawal. There will be interactive partnership with the pharmaceutical industry to facilitate access to stratified populations for novel therapeutic studies.

INTRODUCTION

The Medical Research Council has recently funded an ambitious stratified medicines programme in severe asthma (the UK Refractory Asthma Stratification Programme (RASP-UK) http://www.rasp.org.uk/). In asthma, disease stratification has traditionally followed a ‘one-size fits all’ approach, based on level of asthma control and response to ‘stepwise’ increases in corticosteroid (CS) treatment. More recently, stratification has been based on inflammatory biomarkers, with spurtin analysis and transcriptomic profiling demonstrating that ~30% of patients with asthma have typical eosinophilic airway inflammation driven by ‘Type 2’ cytokines (T2 cytokines: interleukin (IL)-4, IL-5, IL-13); this T2-high asthma has been shown to respond well to CS therapy. In the remainder of patients, there is limited evidence for a major role for T2 cytokines and this has been termed ‘T2-low asthma’, where patients show little or no response to CS therapy. There is also evidence of significant disease heterogeneity in severe asthma, with only 25%–50% of patients having the prototypic T2 gene signature consistent with T2-high disease. In many cases of severe asthma, it therefore seems likely that the CS dose has been escalated inappropriately to try and manage persistent symptoms that are not CS responsive. Given the clear evidence that CS responsiveness is confined to T2-high disease, the cornerstone of the RASP-UK stratification programme is around failure of response to CS therapy in severe asthma.

We propose that in patients with severe asthma, failure to respond to high-dose CS treatment occurs for three principal reasons:

2. Impaired CS responsiveness— in some patients, despite adherence with high-dose inhaled CS, there is persistent T2-high inflammation/eosinophilia and these patients frequently require systemic CS to achieve an acceptable level of disease control.
3. Non-responsive to CS in patients with T2-low asthma—we believe that CS will have been escalated inappropriately in this group in clinical practice.

NON-ADHERENCE TO CS TREATMENT

Non-adherence to inhaled CS and oral CS therapy is a major clinical problem, present in 30%–50% of patients with difficult-to-control asthma. Non-adherence can be intentional or non-intentional, is poorly detected by physicians and asthma nurses and is associated with poor asthma outcomes and increased healthcare costs. Moreover, enrolment of non-adherent patients into clinical trials is believed to contribute to the frequently observed improvement in placebo arms of asthma clinical trials, complicating the interpretation of trial results and reducing statistical power. Importantly, expensive new biological therapies targeting T2-high patients can potentially be used inappropriately in...
patients who would often be controlled with improved adherence to inhaled CS. Patients with difficult-to-control asthma and fractional exhaled nitric oxide (FeNO) >45 ppb have a high risk of exacerbation and the key clinical question is whether failure to control their disease is because of non-adherence to inhaled CS treatment or whether they have relative CS-resistant T2-high asthma and, thus, require additional treatment with drugs that target T2 mechanisms (eg, anti-IL-5 and anti-IL-13 treatments).

RASP-UK will therefore use biomarker-based assessments of inhaled CS exposure and response in biomarker-high patients (‘FeNO suppression test’—reference 4 online supplementary data) using remote monitoring technologies to define CS responsibility and thus optimise inhaled CS where appropriate.

### IMPAIRED CS RESPONSIVENESS

In some patients with severe asthma, despite adherence with high-dose inhaled CS, there is persistent T2-high inflammation and airway eosinophilia and these patients frequently require systemic CS to achieve disease control. The availability of many new biological therapies targeting T2-high disease in the next 5 years will generate many interesting questions, including differential efficacy between monoclonal antibodies targeting IL-5/IL-5R (mepolizumab, bendralizumab, relizumab), IL-13 (lebrikizumab, tralokinumab) and IL-4Rα (dupilumab). Other strategies targeting the T2-axis, including anti-CrTh2 and novel anti-IgE therapies (quilizumab, Medi-4212, QGE031), will also be targeting overlapping patient groups; identifying which patients respond better to different classes of drugs may require ‘head-to-head’ studies. Many of these new therapies are expected to come to market with a companion diagnostic or predictive biomarker(s) of clinical response.

### NON-RESPONSIVENESS TO CS

Inhaled CS remain the mainstay of asthma treatment, controlling disease through suppression of T2/eosinophilic inflammation in the airway. However, not all symptoms in severe asthma respond to CS, and CS responsiveness is minimal in the absence of T2 inflammation. Therefore, new algorithms for guiding CS treatment in patients with severe asthma are needed, which are not solely based on clinical symptoms and lung function and which can be delivered in the clinic. Titrating CS against sputum eosinophilia improves asthma control by reducing asthma exacerbations but this strategy is difficult to deliver in real-world clinical settings. FeNO is straightforward to measure, but when used as a single biomarker, it has been disappointing in titrating CS in patients with moderate asthma. Periostin is a secreted matricellular protein from a number of tissues including airway epithelial cells and is upregulated by T2 cytokines (IL-4 and IL-13) and is associated with airway eosinophilia in patients with severe asthma. An assay for serum periostin is being developed to help identify a periostin-high responder population for the anti-IL-13 monoclonal antibody lebrikizumab.

We have previously examined the predictive value of FeNO, blood eosinophils and serum periostin as a composite biomarker to predict exacerbation risk in the placebo arms of clinical trials with lebrikizumab andomalizumab in patients taking at least 500 μg fluticasone propionate and a second controller (see online supplementary data). This analysis has demonstrated that, individually, these biomarkers are all correlated with exacerbation risk, but using the three biomarkers in a ‘composite’ scoring system further differentiated subjects on the basis of exacerbation rate (see online supplementary figure E1). This predictive composite score is independent of asthma symptoms (measured by asthma control questionnaire) and lung function (see online supplementary figures E2 and E3) which current asthma guidelines advocate for treatment adjustment.

RASP-UK will therefore use this scoring system to adjust CS treatment in a randomised, pragmatic, multicentre, parallel group trial in patients with severe asthma and baseline FeNO <45 ppb comparing standard care with treatment guided by composite biomarkers (as discussed above, patients with FeNO >45 ppb have a high risk of exacerbation and are not candidates for CS reduction). Exploratory outcomes will examine the prognostic value of selected, novel blood and urine biomarkers from the Unbiased BIOmarkers in PREDiction of respiratory disease outcomes (U-BIOPRED) programme for exacerbation risk (http://www.europeana Lung.org/en/projects-and-research/projects/u-biopred/home). The programme will also characterise the inflammatory and microbiomic profiles (viral, bacterial, fungal) in exacerbations in both study arms.

One of the anticipated outcomes of this biomarker-based stratification will be identification of a patient group with T2-low severe asthma who have persistent symptoms and exacerbations which are not CS responsive and in whom T2 inflammation biomarkers (eosinophils, FeNO, periostin) are adequately controlled with moderate doses of inhaled CS. We know that this patient group exists based on data from a comparable sputum stratification study where one-third of patients had a sputum eosinophil count of <1.9% when repeatedly measured over 12 months despite steroid withdrawal. There are currently few treatment options for these patients representing a significant unmet medical need where new targets need to be identified so drugs can be developed. One of the core aims of RASP-UK is to characterise this group in detail to define important structure/function/symptom relationships. This will include transcriptomic and microbiomic profiling compared with age and gender matched patients with refractory eosinophilic asthma and stable asthma controlled with low-dose inhaled CS. These groups will be followed up for 12 months to identify their exacerbation pattern and stability of the phenotype. Previous research has focused on eosinophilia as a prognostic for exacerbation, but ‘non-eosinophilic cohorts’ also experience exacerbations and potent anti-eosinophilic therapies have not eradicated severe exacerbations in clinical trials. A better understanding of the mechanism and phenotype of exacerbations in this T2-low cohort is fundamental to targeting exacerbations in this group.

### CONCLUSION

RASP-UK is a logical, clinically focused, stratification programme which will develop a clinical model to assess and phenotype patients with severe asthma (figure 1). It will identify appropriate patients for novel biological treatments that target the T2-cytokine axis (T2 biomarker high when adherent to high dose inhaled CS), will optimise CS treatment so that excessive CS exposure does not cause unnecessary morbidity and will facilitate a research focus and better understanding in a major area of ‘unmet need’, specifically non-T2/non-CS responsive severe asthma. Harmonised protocols for patient phenotyping will also allow stratified patient groups to enter proof of concept clinical trials which target the biology of their disease rather than using the usual broad inclusion criteria, where many of the patients are unlikely to respond; this will streamline and reduce size for early drug development in severe asthma. The RASP-UK Consortium vision is to effect a paradigm shift in asthma care through a logical stratified approach to severe asthma and to establish a long-term collaborative infrastructure for translational research excellence in the UK.
Severe Asthma
- ATS/ERS guidelines criteria
- Persistent poor control and/or exacerbations despite high dose therapy (defined as at least 1000μg Fluticasone Propionate (FP) equivalent per day and a second controller)

Adherence Stratification
- FeNO suppression testing
- Prednisolone / cortisol levels (if relevant)
- Novel corticosteroid exposure / adherence biomarkers

Biomarker Corticosteroid Optimisation Stratification
- Composite T2 biomarker steroid reduction algorithm (FeNO, periostin, blood eosinophils)
- When ‘patient’ biomarker profile changes, return to prior corticosteroid dose (optimised dose)

Non-adherent

Adherent / T2 Biomarker High

Remains T2 biomarker high during corticosteroid optimisation and adherent with high dose inhaled corticosteroids / oral corticosteroids

T2-High Severe Asthma
- Persistent asthma symptoms
- T2 biomarker high despite high dose inhaled steroids / oral corticosteroids

T2-High clinical trials

T2-Low Severe Asthma
- Persistent asthma symptoms
- T2 biomarker low on ≤500 μg FP

T2-Low clinical trials

Detailed Clinical Phenotyping
T2-Low Clinical Trials

Figure 1  Flow diagram for the RASP-UK Clinical Stratification Programme. ATS, American Thoracic Society; ERS, European Respiratory Society; FeNO, fractional exhaled nitric oxide; FP, Fluticasone Propionate; RASP-UK, UK Refractory Asthma Stratification Programme.
Research in Progress – Medical Research Council Refractory Asthma Stratification Consortium –
Online Supplement

Liam G Heaney¹, Ratko Djukanovic², Ashley Woodcock³, Samantha Walker⁴, John G. Matthews⁵, Ian D Pavord⁶, Peter Bradding⁷, Robert Niven³, Chris E Brightling⁷, Rekha Chaudhuri⁸, Joseph R. Arron⁵, David F. Choy⁵, Douglas Cowan⁸, Adel Mansur⁹, Andrew Menzies-Gow¹⁰, Ian Adcock¹¹, Kian F Chung¹¹, Chris Corrigan¹², Peter Coyle¹, Timothy Harrison¹³, Sebastian Johnston¹¹, Peter Howarth², James Lordan¹⁴, Ian Sabroe¹⁵, Jeannette Bigler¹⁶, Dirk Smith¹⁶, Matthew Cattley¹⁷, Richard May¹⁷, Lisa Pierre¹⁸, Chris Stevenson¹⁸, Glenn Crater¹⁹, Frank Keane²⁰, Costello RW²¹, Val Hudson²², David Supple²², Tim Hardman²³.

RASP-UK Consortium Partners – ¹The Queen's University of Belfast, ²University of Southampton, ³The University of Manchester, ⁴Asthma UK, ⁵Genentech Inc., ⁶The University of Oxford, ⁷University of Leicester, ⁸Greater Glasgow Health Board, ⁹Heart of England NHS Foundation Trust, ¹⁰Royal Brompton & Harefield NHS Foundation Trust, ¹¹Imperial College of Science, Technology and Medicine, ¹²Kings College London, ¹³University of Nottingham, ¹⁴The Newcastle upon Tyne NHS Foundation Trust, ¹⁵University of Sheffield, ¹⁶Amgen Inc., ¹⁷Astra Zeneca, ¹⁸Janssen Research & Development LLC, ¹⁹Aerocrine AB, ²⁰Vitalograph, ²¹Royal College of Surgeons Ireland, ²²Public and Patient Representative, ²³Niche Science & Technology.

Address for Correspondence:
Professor Liam Heaney
Centre for Infection and Immunity, Queen’s University of Belfast,
Level 8, Belfast City Hospital,
Lisburn Road, Belfast,
Northern Ireland, UK.
BT9 7AB.

Telephone: ++44 (0)28 90 26 3821
Fax: ++44 (0)28 90 26 3879
Email: l.heaney@qub.ac.uk
Non-adherence to corticosteroid treatment

Non-adherence to medication in asthma is common, yet poorly detected by physicians, and is associated with poor asthma outcomes and increased healthcare costs (1,2,3). To maximise benefits to patients and provide cost-effective treatment strategies, it is essential to develop objective biomarker strategies to confirm whether patients are adhering to their inhaled corticosteroids or whether they have corticosteroid-unresponsive inflammation.

Our Consortium has demonstrated that the fall in fractional exhaled nitric oxide (FeNO) from baseline after a directly observed inhaled corticosteroid (ICS) challenge (daily for 7 days) distinguishes asthmatic patients with steroid-insensitive T2-High asthma, (where FeNO levels remain high despite ICS treatment), from those who are non-adherent with ICS, in whom a marked fall in FeNO (>40% from baseline) occurs with directly observed treatment (4). We have thus defined a functional biomarker test ("FeNO suppression test") of ICS exposure in patients with asthma with an initial FeNO >45ppb. The RASP-UK programme will combine the use remote monitoring technology (Aerocrine NIOX MINO Data Management Program) plus Smart inhaler technology (Vitalograph INCA device, see reference 5) to monitor concurrent FeNO and ICS use.

Non-responsiveness to corticosteroids

We have previously examined the predictive value of using FeNO, blood eosinophils and periostin as a composite biomarker to predict exacerbation risk in the placebo arms of clinical trials conducted with lebrikizumab and with omalizumab in patients taking at least 500 μg fluticasone propionate and a second controller (6,7,8). This analysis has demonstrated that:

- individually, all of these biomarkers are correlated with exacerbation risk, but including the three biomarkers in a "composite" scoring system further differentiated subjects on the basis of exacerbation rate (figure E1);

- the composite score is calculated from the individual biomarkers as the average of all three biomarker scores, rounded to the nearest integer, to give the "composite score" [score of 0, 1 or 2 – Table E1]. A higher score predicts a significantly greater exacerbation risk, with a score of 2 associated with a 2-fold higher risk of exacerbation compared with the minimum score of 0;
- the composite score is independent of asthma symptoms (as assessed by asthma control questionnaire [ACQ, figure E2] and lung function (FEV₁, Figure E3) which current asthma guidelines advocate for treatment adjustment;

- the composite scoring system allows identification of a ‘low-risk’ patients with a low exacerbation rate where we believe we can safely reduce corticosteroid dose in this group

Using this straightforward biomarker score to adjust corticosteroids, RASP-UK will conduct a randomised, pragmatic, multi-centre, parallel group trial in patients with severe asthma (persistent symptoms despite treatment with at least 1000 ug fluticasone propionate) and initial FeNO <45 ppb [as discussed previously, patients with FeNO >45 ppb have a high risk of exacerbation (9), so these patients are NOT candidates for corticosteroid reduction]. RASP-UK will compare a composite biomarker based strategy to adjust corticosteroid treatment compared with standard care and the primary outcome will be the proportion of patients with any reduction in ICS or oral CS dose from baseline to Week 48.

The study will also explore the prognostic value of the individual and composite biomarkers in predicting severe exacerbations and examine additional novel blood biomarkers for eosinophilic inflammation identified by the UBIOPRED programme [http://www.europealung.org/en/projects-and-research/projects/u-biopred/home]. It will also focus on the inflammatory and microbiomic profiles in patients during exacerbations to confirm biomarker-stratified patients are non-eosinophilic during these events.

RASP-UK will explore potential collaborative engagement with new partners over the duration of the programme. This will be by agreement of the Executive Management Team and the Medical Research Council. For clinical sites, this would require that additional resource be provided from an external funding source.
References


Legends to Figures Online Supplement

**Figure E1** - A higher composite biomarker score further differentiated subjects on the basis of exacerbation rate (mean, 95% CI), with a composite biomarker score of 2 having a 2-fold higher risk of exacerbation compared to the composite score of 0.

**Figure E2 and E3** – The composite biomarker has no relationship with symptoms [figure E2 - Asthma Control Questionnaire, ACQ5] or lung function [ figure E3 - FEV1% predicted] which are usually used to up-titrate corticosteroids.
Table E1. The composite biomarker score is calculated from the individual biomarker scores and is the AVERAGE of all 3 scores rounded to the nearest integer to give the "composite score" [score of 0, 1 or 2]

<table>
<thead>
<tr>
<th>Biomarker Score</th>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>FeNO (ppb)</td>
<td>&lt;15</td>
<td>15 - &lt;30</td>
<td>≥30</td>
</tr>
<tr>
<td>Blood eosinophil count (N/μL)</td>
<td>&lt; 150</td>
<td>150 - &lt;300</td>
<td>≥300</td>
</tr>
<tr>
<td>Periostin (ng/ml)</td>
<td>&lt;45</td>
<td>45 - &lt;55</td>
<td>≥55</td>
</tr>
</tbody>
</table>
Figure E1

Unadjusted Exacerbation Rate/Year (95% CI)

Composite Score (Periostin/FeNO/Blood Eos)